Publications by authors named "Ilya Giverts"

Background: Post-exercise oxygen uptake recovery (VORec) is slow in advanced heart failure. We sought to establish easily derived VORec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VORec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.

View Article and Find Full Text PDF

Objectives: Regional differences in heart failure with preserved ejection fraction (HFpEF) care have been reported. We aimed to assess a physician-reported HFpEF management in the Russian Federation (RF) and a variation in the diagnosis and treatment of HFpEF between the RF and the European Union (EU).

Design/settings: It is a post hoc analysis of an academic web-based international HFpEF designed as a cross-sectional survey and conducted between May 2023 and July 2023.

View Article and Find Full Text PDF

The management of heart failure with preserved ejection fraction (HFpEF) remains largely unresolved due to our limited understanding of the underlying mechanisms of the pathology and the challenges in accurately phenotyping this heterogeneous syndrome. A paradigm shift is required to personalise care and unify our approaches to HFpEF patients for future clinical trials. Accordingly, we propose a staging classification for HFpEF based on the identification of the involved cardiac chambers by echocardiography.

View Article and Find Full Text PDF

This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology.

View Article and Find Full Text PDF
Article Synopsis
  • Cardiac amyloidosis (CA) is an often overlooked cause of heart failure (HF), highlighting the importance of early detection and timely therapy for better patient outcomes.
  • A global survey with 1,460 physicians revealed that while many have experience diagnosing CA in patients with preserved ejection fraction (HFpEF), systematic screening is not widely practiced, with only 10% conducting routine checks.
  • There is significant variability in screening and management strategies for CA, indicating a need for better education and access to disease-modifying therapies within the HF community.
View Article and Find Full Text PDF
Article Synopsis
  • - Glucagon-like peptide-1 (GLP-1) receptor agonists are new diabetes and obesity treatments that also show potential cardiovascular benefits for patients with type 2 diabetes.
  • - These medications are getting attention for their impact on heart failure (HF) outcomes, similar to other diabetes drugs like sodium-glucose cotransporter 2 inhibitors.
  • - Current research on GLP-1 receptor agonists in heart failure patients is limited and often inconclusive, focusing on their effects on heart structure, exercise capacity, and quality of life, suggesting a need for larger clinical trials.
View Article and Find Full Text PDF

Background: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being.

Methods: VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied.

View Article and Find Full Text PDF

Being commonly diagnosed in elderly women and associated with comorbidities as well as ageing-related cardio-vascular changes, heart failure with preserved ejection fraction (HFpEF) has been recently considered as a distinct cardiogeriatric syndrome. Frailty is another frequent geriatric syndrome. HFpEF and frailty share common underlying mechanisms, often co-exist, and represent each other's risk factors.

View Article and Find Full Text PDF

State-of-the-art therapy improves the five-year survival rate of patients under the age of 20 with cranial and craniospinal tumors by up to 74%. The urgency of dealing effectively with late treatment-associated cardiovascular complications is rising. : We aimed to assess echocardiographic parameters and exercise performance in subjects with a history of complex treatment for cranial and craniospinal tumors in childhood.

View Article and Find Full Text PDF

Background: Whether systemic oxygen levels (SaO) during exercise can provide a window into invasively derived exercise hemodynamic profiles in patients with undifferentiated dyspnea on exertion is unknown.

Methods: We performed cardiopulmonary exercise testing with invasive hemodynamic monitoring and arterial blood gas sampling in individuals referred for dyspnea on exertion. Receiver operator analysis was performed to distinguish heart failure with preserved ejection fraction from pulmonary arterial hypertension.

View Article and Find Full Text PDF
Article Synopsis
  • Recent guidelines suggest starting four key heart failure (HF) medications for patients with reduced ejection fraction (HFrEF) at once, but there's uncertainty about how cardiologists view this approach compared to HF specialists.
  • A survey with 615 cardiologists globally revealed that most prefer a traditional sequential treatment method, starting with ACE inhibitors or other recommended therapies.
  • Although many agree that beginning all four medications during initial hospitalization is doable, there's still a preference for the classic approach, indicating a need for research to alter treatment practices.
View Article and Find Full Text PDF

Background: Electrical muscle stimulation (EMS) is being evaluated as a possible alternative to exercise training to improve functional capacity in severely deconditioned patients with heart failure (HF). However, there is insufficient data on delayed effects of EMS starting early after decompensation. The aim of this study was to determine the impact of a short inpatient EMS intervention in severely deconditioned patients with HF on functional capacity and quality of life (QoL) over a follow-up period of 1 month.

View Article and Find Full Text PDF

Aim: To develop an algorithm for optimization of rate-adaptive pacing settings in heart failure patients with preserved ejection fraction (HFpEF) and permanent cardiac pacing.

Methods: This is a prospective randomized controlled study. A total of 54 patients with HFpEF, permanent atrial fibrillation (AF), and VVIR pacing were randomized to an intervention group with optimization of rate-adaptation parameters by using cardiopulmonary exercise testing (CPET) and pacemaker stress echocardiography (PASE), and to a control group with conventional programming.

View Article and Find Full Text PDF

Aims To evaluate safety and efficacy of moderate intensity interval exercise training early after heart failure decompensation on exercise tolerance and health-related quality of life (HRQoL). Methods and results This is a prospective randomized controlled study. We screened 234 consecutive patients admitted with decompensated heart failure; 46 patients (42 men/4 women; 61 ± 12 years of age) were randomized to a moderate intensity aerobic interval training ( n = 24) or to a control group ( n = 22).

View Article and Find Full Text PDF